Glosun Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 21 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
- Revenue Growth 35.83%
- Profit Growth 5.40%
- Ebitda 147.10%
- Net Worth 19.95%
- Total Assets 13.69%
About Glosun Pharmaceuticals
Glosun Pharmaceuticals Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 January 2004 and has a history of 21 years and one month. Its registered office is in Cuttack, Odisha, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.00 M.
Mamata Talasu and Biswanath Talasu serve as directors at the Company.
Company Details
- Location
Cuttack, Odisha, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51397OR2004PTC007466
- Company No.
007466
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jan 2004
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Who are the key members and board of directors at Glosun Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mamata Talasu  | Director | 23-Mar-2012 | Current |
| Biswanath Talasu | Director | 23-Mar-2012 | Current |
Financial Performance of Glosun Pharmaceuticals.
Glosun Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 35.83% increase. The company also saw a slight improvement in profitability, with a 5.4% increase in profit. The company's net worth Soared by an impressive increase of 19.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glosun Pharmaceuticals?
In 2018, Glosun Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Adinarayan Associates Private LimitedMamata Talasu and Biswanath Talasu are mutual person
Charges (Loans)
₹5.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Aug 2020 | Others | ₹5.00 M | Open |
How Many Employees Work at Glosun Pharmaceuticals?
Unlock and access historical data on people associated with Glosun Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glosun Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glosun Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
